98 related articles for article (PubMed ID: 1372663)
21. Comparison of anti-desmin and anti-actin staining for the computerized analysis of cavernous smooth muscle density.
Sattar AA; Haot J; Schulman CC; Wespes E
Br J Urol; 1996 Feb; 77(2):266-70. PubMed ID: 8800897
[TBL] [Abstract][Full Text] [Related]
22. Quantitative peroxidase-antiperoxidase complex-substrate mass determination in tissue sections by a dual wavelength method.
Zhou R; Parker DL; Hammond EH
Anal Quant Cytol Histol; 1992 Apr; 14(2):73-80. PubMed ID: 1590900
[TBL] [Abstract][Full Text] [Related]
23. Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men?
Byun SS; Jeong H; Jo MK; Lee E
Urology; 2005 Sep; 66(3):593-6. PubMed ID: 16140084
[TBL] [Abstract][Full Text] [Related]
24. [Is a single prostatic biopsy sufficient for selection of medical treatment in benign prostatic hypertrophy?].
Zlotta AR; Sattar AA; Wespes E; Haot J; Schulman CC
Acta Urol Belg; 1995 Mar; 63(1):83-7. PubMed ID: 7537013
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue.
Kitada S; Kumazawa J
J Urol; 1987 Jul; 138(1):158-60. PubMed ID: 2439708
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous demonstration of lectin-binding sites and antigens detected by monoclonal antibodies in a parallelized double-staining technique: a highly discriminative and quickly developing technique for frozen sections.
Mechtersheimer G; Möller P; Momburg F; Moldenhauer G; Schwechheimer K
J Histochem Cytochem; 1986 Mar; 34(3):399-402. PubMed ID: 2419393
[TBL] [Abstract][Full Text] [Related]
27. The relative amount of epithelium, muscle, connective tissue and lumen in prostatic hyperplasia as a function of the mass of tissue resected.
Schuster GA; Schuster TG
J Urol; 1999 Apr; 161(4):1168-73. PubMed ID: 10081863
[TBL] [Abstract][Full Text] [Related]
28. Relationship between urodynamic type of obstruction and histological component of the prostate in patients with benign prostatic hyperplasia.
Ichiyanagi O; Sasagawa I; Ishigooka M; Suzuki Y; Nakada T
Eur Urol; 1999 Sep; 36(3):203-6. PubMed ID: 10450003
[TBL] [Abstract][Full Text] [Related]
29. Binding and functional properties of alpha 1 adrenoceptors and area density of smooth muscle in the canine prostate.
Lepor H; Tang R; Meretyk S; Hartanto V; Shapiro E
J Urol; 1992 Oct; 148(4):1310-3. PubMed ID: 1328693
[TBL] [Abstract][Full Text] [Related]
30. Transrectal real-time tissue elastography - an effective way to distinguish benign and malignant prostate tumors.
Zhang Y; Tang J; Liang HD; Lv FQ; Song ZG
Asian Pac J Cancer Prev; 2014; 15(4):1831-5. PubMed ID: 24641417
[TBL] [Abstract][Full Text] [Related]
31. Alkaline phosphatase and peroxidase for double immunoenzymatic labelling of cellular constituents.
Mason DY; Sammons R
J Clin Pathol; 1978 May; 31(5):454-60. PubMed ID: 77279
[TBL] [Abstract][Full Text] [Related]
32. Atypical stromal smooth muscle hyperplasia of prostate.
Leong SS; Vogt PJ; Yu GS
Urology; 1988 Feb; 31(2):163-7. PubMed ID: 2448943
[TBL] [Abstract][Full Text] [Related]
33. [The histochemistry of complex carbohydrates in the prostatic tumor].
Sugiyama T
Hinyokika Kiyo; 1985 Jan; 31(1):49-69. PubMed ID: 2581429
[TBL] [Abstract][Full Text] [Related]
34. Phosphotyrosine antibodies preferentially react with basal epithelial cells in the dog prostate.
Landry F; Chapdelaine A; Bégin LR; Chevalier S
J Urol; 1996 Jan; 155(1):386-90. PubMed ID: 7490893
[TBL] [Abstract][Full Text] [Related]
35. Regulation of prostatic smooth muscle contractility by intracellular second messengers: implications for the conservative treatment of benign prostatic hyperplasia.
Eckert RE; Schreier U; Drescher P; Madsen PO; Derouet H; Becht E; Steffens J; Ziegler M
Urol Int; 1995; 54(1):6-21. PubMed ID: 7539557
[TBL] [Abstract][Full Text] [Related]
36. Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study.
Zlotta AR; Raviv G; Peny MO; Noel JC; Haot J; Schulman CC
J Urol; 1997 Mar; 157(3):894-9. PubMed ID: 9072594
[TBL] [Abstract][Full Text] [Related]
37. The prevention of benign prostatic hyperplasia (bph).
Roper WG
Med Hypotheses; 2017 Mar; 100():4-9. PubMed ID: 28236846
[TBL] [Abstract][Full Text] [Related]
38. Semiquantitative study of the distribution of two cellular antigens by computer-directed color analysis.
Lamaziere JM; Lavallee J; Zunino C; Larrue J
Lab Invest; 1993 Feb; 68(2):248-52. PubMed ID: 7680084
[TBL] [Abstract][Full Text] [Related]
39. The value of power Doppler imaging to predict the histologic components of benign prostatic hyperplasia.
Hayami S; Ushiyama T; Kurita Y; Kageyama S; Suzuki K; Fujita K
Prostate; 2002 Oct; 53(2):168-74. PubMed ID: 12242732
[TBL] [Abstract][Full Text] [Related]
40. Correlations between parameters in pressure-flow analysis and histological compositions in prostate in patients with benign prostatic hyperplasia.
Ichiyanagi O; Nakada T
Urol Int; 1997; 59(3):154-60. PubMed ID: 9428431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
